Treating sickle cell disease by targeting HbS polymerization.
暂无分享,去创建一个
[1] K. Ataga,et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease , 2017, The New England journal of medicine.
[2] C. Johnson,et al. Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin , 2017, ACS medicinal chemistry letters.
[3] E. Henry,et al. Kinetic assay shows that increasing red cell volume could be a treatment for sickle cell disease , 2017, Proceedings of the National Academy of Sciences.
[4] R. Ware,et al. Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research. , 2017, Blood.
[5] J. Simon,et al. SCD-101: A New Anti-Sickling Drug Reduces Pain and Fatigue and Improves Red Blood Cell Shape in Peripheral Blood of Patients with Sickle Cell Disease , 2016 .
[6] K. Bridges,et al. Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor , 2016 .
[7] E. Fuchs,et al. Allogeneic stem cell transplantation for sickle cell disease , 2016, Current opinion in hematology.
[8] G. Kato,et al. New developments in anti‐sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo? , 2016, British journal of haematology.
[9] G. Lettre,et al. Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies , 2016, The Lancet.
[10] Matthew C. Canver,et al. Customizing the genome as therapy for the β-hemoglobinopathies. , 2016, Blood.
[11] G. Kato. New insights into sickle cell disease: mechanisms and investigational therapies , 2016, Current opinion in hematology.
[12] W. Eaton,et al. Universality of supersaturation in protein-fiber formation , 2016, Nature Structural &Molecular Biology.
[13] M. Telen. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. , 2016, Blood.
[14] B. Ogutu,et al. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. , 2016, The New England journal of medicine.
[15] R. Ware. Optimizing hydroxyurea therapy for sickle cell anemia. , 2015, Hematology. American Society of Hematology. Education Program.
[16] K. Dufu,et al. GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease , 2015 .
[17] B. Metcalf,et al. GBT440 Demonstrates High Specificity for Red Blood Cells in Nonclinical Species , 2015 .
[18] C. Brugnara,et al. 2015 Clinical trials update in sickle cell anemia , 2015, American journal of hematology.
[19] E. Henry,et al. Experiments on Hemoglobin in Single Crystals and Silica Gels Distinguish among Allosteric Models. , 2015, Biophysical journal.
[20] K. Ataga,et al. The trials and hopes for drug development in sickle cell disease , 2015, British journal of haematology.
[21] Nupur K. Das,et al. Intestine-specific Disruption of Hypoxia-inducible Factor (HIF)-2α Improves Anemia in Sickle Cell Disease* , 2015, The Journal of Biological Chemistry.
[22] F. Ferrone. The delay time in sickle cell disease after 40 years: A paradigm assessed , 2015, American journal of hematology.
[23] M. Telen,et al. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. , 2015, Blood.
[24] R. Hebbel,et al. Sickle cell disease: renal manifestations and mechanisms , 2015, Nature Reviews Nephrology.
[25] G. Mensah,et al. An analysis of the NIH-supported sickle cell disease research portfolio. , 2015, Blood cells, molecules & diseases.
[26] J. P. McCoy,et al. Imaging flow cytometry for automated detection of hypoxia‐induced erythrocyte shape change in sickle cell disease , 2014, American journal of hematology.
[27] Paola Sebastiani,et al. Fetal hemoglobin in sickle cell anemia: a glass half full? , 2013, Blood.
[28] K. Ataga,et al. A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. , 2012, Thrombosis research.
[29] Daniel E Bauer,et al. Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders. , 2012, Blood.
[30] Cong Peng,et al. Correction of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin Silencing , 2011, Science.
[31] J. Tisdale,et al. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. , 2011, Blood.
[32] M. Gladwin,et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. , 2011, Blood.
[33] Eric T. Kim,et al. How does a drug molecule find its target binding site? , 2011, Journal of the American Chemical Society.
[34] K. Ataga,et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso‐occlusive crises in patients with sickle cell disease: a phase III randomized, placebo‐controlled, double‐blind study of the gardos channel blocker senicapoc (ICA‐17043) , 2011, British journal of haematology.
[35] M. Gladwin,et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. , 2011, JAMA.
[36] S. Thein,et al. Sickle cell disease in a carrier with pyruvate kinase deficiency , 2008, Hematology.
[37] J. Hirschhorn,et al. Supporting Online Material Materials and Methods Figs. S1 to S10 Tables S1 to S7 References Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-specific Repressor Bcl11a , 2022 .
[38] K. Ataga,et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. , 2008, Blood.
[39] P. Frenette,et al. Sickle cell disease: old discoveries, new concepts, and future promise. , 2007, The Journal of clinical investigation.
[40] D. Abraham,et al. 5‐hydroxymethyl‐2‐furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells †,‡ , 2005, British journal of haematology.
[41] William A Eaton,et al. Understanding the shape of sickled red cells. , 2005, Biophysical journal.
[42] T. Asakura,et al. Niprisan (Nix‐0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions , 2003, British journal of haematology.
[43] J. Stocker,et al. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. , 2003, Blood.
[44] W. Eaton. Linus Pauling and sickle cell disease. , 2002, Biophysical chemistry.
[45] T. Asakura,et al. In vitro effects of NIPRISAN (Nix‐0699): a naturally occurring, potent antisickling agent , 2002, British journal of haematology.
[46] K. Ataga,et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. , 2001, JAMA.
[47] A. Duits,et al. Low adjusted‐dose acenocoumarol therapy in sickle cell disease: A pilot study , 2001, American journal of hematology.
[48] Andrea Mozzarelli,et al. Is cooperative oxygen binding by hemoglobin really understood? , 1999, Nature Structural Biology.
[49] D. Bachir,et al. A new sickle cell disease phenotype associating Hb S trait, severe pyruvate kinase deficiency (PK Conakry), and an α2 globin gene variant (Hb Conakry) , 1998, British journal of haematology.
[50] H. Bunn. Pathogenesis and treatment of sickle cell disease. , 1997, The New England journal of medicine.
[51] M L Terrin,et al. Hydroxyurea and Sickle Cell Anemia Clinical Utility of a Myelosuppressive “Switching” Agent , 1996, Medicine.
[52] J. Kark,et al. Antisickling effects of 2,3-diphosphoglycerate depletion. , 1995, Blood.
[53] J. Hofrichter,et al. The biophysics of sickle cell hydroxyurea therapy. , 1995, Science.
[54] M L Terrin,et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. , 1995, The New England journal of medicine.
[55] O. Castro,et al. Improvement of sickle cell anemia by iron‐limited erythropoiesis , 1994, American journal of hematology.
[56] A. Schechter,et al. Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiologic ligand saturations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[57] B. Kim,et al. 2,3-Diphosphoglycerate and intracellular pH as interdependent determinants of the physiologic solubility of deoxyhemoglobin S. , 1990, Blood.
[58] M. Goldberg,et al. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. , 1990, The New England journal of medicine.
[59] J. Hofrichter,et al. Hemoglobin S gelation and sickle cell disease. , 1987, Blood.
[60] J. Hofrichter,et al. Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo. , 1987, Science.
[61] E. Padlan,et al. Refined crystal structure of deoxyhemoglobin S. II. Molecular interactions in the crystal. , 1985, The Journal of biological chemistry.
[62] J. Hofrichter,et al. Kinetics of sickle hemoglobin polymerization. II. A double nucleation mechanism. , 1985, Journal of molecular biology.
[63] J. Hofrichter,et al. Kinetics of sickle hemoglobin polymerization. I. Studies using temperature-jump and laser photolysis techniques. , 1985, Journal of molecular biology.
[64] S. Orkin,et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. , 1984, The Journal of clinical investigation.
[65] H. Bunn,et al. Hemoglobin: Molecular, Genetic and Clinical Aspects , 1984 .
[66] A. Schechter,et al. Intracellular polymerization of sickle hemoglobin. Effects of cell heterogeneity. , 1983, The Journal of clinical investigation.
[67] J. Greenberg,et al. Trial of low doses of aspirin as prophylaxis in sickle cell disease. , 1983, The Journal of pediatrics.
[68] N. Mohandas,et al. Hydration of sickle cells using the sodium ionophore Monensin. A model for therapy. , 1982, The Journal of clinical investigation.
[69] J. Hofrichter,et al. Oxygen binding by sickle cell hemoglobin polymers. , 1982, Journal of molecular biology.
[70] H. Bunn. Evolution of mammalian hemoglobin function. , 1981, Blood.
[71] F. Epstein,et al. A study of induced hyponatremia in the prevention and treatment of sickle-cell crisis. , 1980, The New England journal of medicine.
[72] R. Edalji,et al. Solubilization of hemoglobin S by other hemoglobins. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[73] J. Eaton,et al. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. , 1980, The New England journal of medicine.
[74] D. Labie,et al. β-Chain contact sites in the haemoglobin S polymer , 1980, Nature.
[75] J. Hofrichter,et al. Gelation of sickle cell hemoglobin in mixtures with normal adult and fetal hemoglobins. , 1979, Journal of molecular biology.
[76] J. Hofrichter,et al. Requirements for therapeutic inhibition of sickle haemoglobin gelation , 1978, Nature.
[77] S. Edelstein,et al. Three-dimensional reconstruction of the fibres of sickle cell haemoglobin , 1978, Nature.
[78] R. Edalji,et al. Location and bond type of intermolecular contacts in the polymerisation of haemoglobin S , 1977, Nature.
[79] J. Hofrichter,et al. Thermodynamics of gelation of sickle cell deoxyhemoglobin. , 1977, Journal of molecular biology.
[80] M. Goldberg,et al. Participation of hemoglobins A and F in polymerization of sickle hemoglobin. , 1977, The Journal of biological chemistry.
[81] A. Minton,et al. Analysis of non-ideal behavior in concentrated hemoglobin solutions. , 1977, Journal of molecular biology.
[82] A. Minton. Non-ideality and the thermodynamics of sickle-cell hemoglobin gelation. , 1977, Journal of molecular biology.
[83] Z. B. Rose. A procedure for decreasing the level of 2,3-bisphosphoglycerate in red cells in vitro. , 1976, Biochemical and biophysical research communications.
[84] J. Hofrichter,et al. Supersaturation in sickle cell hemoglobin solutions. , 1976, Proceedings of the National Academy of Sciences of the United States of America.
[85] K. B. Ward,et al. Crystal structure of sickle-cell deoxyhemoglobin at 5 A resolution. , 1975, Journal of molecular biology.
[86] E. Beutler. The effect of carbon monoxide on red cell life span in sickle cell disease. , 1975, Blood.
[87] J. Hofrichter,et al. Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[88] H. Bunn,et al. Asymmetrical hemoglobin hybrids. An approach to the study of subunit interactions. , 1974, Biochemistry.
[89] E. Beutler,et al. The effect of 2,3-DPG on the sickling phenomenon. , 1971, Blood.
[90] J. Bertles,et al. Hemoglobin Interaction: Modification of Solid Phase Composition in the Sickling Phenomenon , 1970, Science.
[91] Z. B. Rose,et al. 2,3-diphosphoglycerate phosphatase from human erythrocytes. General properties and activation by anions. , 1970, The Journal of biological chemistry.
[92] H. Bunn,et al. Control of hemoglobin function within the red cell. , 1970, The New England journal of medicine.
[93] H. Bunn,et al. The interaction of 2,3-diphosphoglycerate with various human hemoglobins. , 1970, The Journal of clinical investigation.
[94] R. Benesch,et al. Intracellular Organic Phosphates as Regulators of Oxygen Release by Haemoglobin , 1969, Nature.
[95] J. Changeux,et al. ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. , 1965, Journal of molecular biology.
[96] E. Beutler. The effect of methemoglobin formation in sickle cell disease. , 1961, Journal of Clinical Investigation.
[97] L. Pauling,et al. Sickle cell anemia a molecular disease. , 1949, Science.
[98] E. Ponder. THE TONICITY-VOLUME RELATIONS FOR SYSTEMS CONTAINING HUMAN RED CELLS AND THE CHLORIDES OF MONOVALENT CATIONS , 1949, The Journal of general physiology.
[99] J. Davies,et al. Gene Therapy in a Patient with Sickle Cell Disease. , 2017, The New England journal of medicine.
[100] M. Gladwin,et al. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. , 2007, Blood reviews.
[101] K. Ataga,et al. Hypercoagulability in sickle cell disease: new approaches to an old problem. , 2007, Hematology. American Society of Hematology. Education Program.
[102] William,et al. Delay Time of Gelation : A Possible Determinant of Clinical Severity in Sickle Cell Disease , 2005 .
[103] John D. Martin,et al. Glass Half Full , 2017, American Journal of Neuroradiology.
[104] N. Enwerem,et al. Efficacy of niprisan in the prophylactic management of patients with sickle cell disease , 2001 .
[105] C. Wambebe,et al. Double-blind, placebo-controlled, randomised cross-over clinical trial of NIPRISAN in patients with Sickle Cell Disorder. , 2001, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[106] D. Abraham,et al. Vanillin, a potential agent for the treatment of sickle cell anemia. , 1991, Blood.
[107] J. Hofrichter,et al. Sickle cell hemoglobin polymerization. , 1990, Advances in protein chemistry.
[108] J. White,et al. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. , 1980, The Journal of clinical investigation.
[109] J. Hofrichter,et al. Editorial: Delay time of gelation: a possible determinant of clinical severity in sickle cell disease. , 1976, Blood.
[110] The Bohr Effect and Combination with Organic Phosphates , 1970, Nature.
[111] H. Bunn,et al. The interaction of 2,3-diphosphoglycerate with various human hemoglobins. , 1970, The Journal of clinical investigation.